STUDY OF THE ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY OF A NEW NON-OPIOID ANALGESIC BASED ON A SELECTIVE INHIBITOR OF TRPA1 ION CHANNELS

The aim is to study the analgesic and anti-inflammatory activity of an innovative molecule under the ZC02-0012 laboratory code belonging to the group of selective blockers of the TRPA1 ion channel.

Materials and methods. The study of the ZC02-0012 analgesic activity was carried out by the hot plate and acetic acid writhing tests. The hot plate test was performed on white laboratory mice. ZC02-0012 substance was administered in doses of 1, 3 and 9 mg/kg. Ketorol at a dose of 3.48 mg/kg was chosen as the reference drug. To study the analgesic effects in the hot plate test, intact white laboratory mice were placed on a preheated at 55°C plate to determine the base level of pain sensitivity. Then the test substances were administered to the animals divided into groups, and the hot plate test was repeated after 30, 60, 90 and 120 minutes. To study the analgesic effects in the test of acetic acid writhing, white laboratory rats were injected with the ZC02-0012 substance at doses of 0.46, 1.38, and 4.15 mg/kg. Ketorol at a dose of 1.6 mg/kg was chosen as the reference drug. 30 minutes after intramuscular injection and 60 minutes after intragastric administration, the intraperitoneal administration of a 0.75% solution of acetic acid was carried out at the rate of 1 ml per 100 g of animal weight. Counting the number of writhings started 15 minutes after the injection of acetic acid and continued for 30 minutes. The anti-inflammatory effects of the ZC02-0012 substance were studied using a model of acute exudative inflammation in response to the subplantar introduction of 0.02 ml of 2% formaldehyde aqueous solution into the right hind paw of the mouse. 4 hours after the phlogistic introduction, the mass of the edematous paw was evaluated. ZC02-0012 substance at doses of 1, 3 and 9 mg/kg and the Diclofenac reference drug at a dose of 13.91 mg/kg were administered intragastrically or intramuscularly 45 minutes before the introduction of phlogistic. The presence and severity of anti-inflammatory activity was judged by the inhibitory effect, expressed in percentage.

Results. The analgesic activity of ZC02-0012 is found to exceed that for Ketorol in both the intramuscular and intragastric ways of administration according to the results of hot plate tests in doses of 3 and 9 mg/kg and acetic acid writhing in doses of 1.38 and 4.15 mg/kg, while the anti-inflammatory activity of ZC02-0012 at doses of 3 and 9 mg/kg is shown to be comparable to that of Diclofenac. Conclusion. The innovative molecule under the ZC02-0012 laboratory code is established to exhibit a pronounced analgesic and anti-inflammatory activity, thus being prospective for further research.

Conflict of interest: the authors declare no conflict of interest.

1. Danilov A.B. Novye podkhody v lechenii patsientov s khronicheskoi bol’yu. URL: http://www.lvrach. ru/2009/04/7634652/ (In Russ.).

2. The Societal Impact of Pain. European positioning statement: chronic pain fundamental for European health. International multi-stakeholder platform acknowledges chronic pain as disease in its ownEuropean policy-makers challenged to respond. 2012. [Accessed on June 27, 2012]. Accessed from http://www.sip-platform.eu/sip-2012.html.

3. Gwyther L., Brennan F., Harding R. Advancing palliative care as a human right. J. Pain Symptom Manage. 2009; 38(5): 767–774. DOI: 10.1016/j.jpainsymman.2009.03.003

4. Hall J.K., Boswell M.V. Ethics, law, and pain management as a patient right. Pain Physician. 2009; 12(3): 499–506.

5. Varrassi G., Müller-Schwefe G, Pergolizzi J. et al. Pharmacological treatment of chronic pain — the need for CHANGE. Curr. Med. Res. Opin. 2010; 26(5): 1231–1245. DOI: 10.1185/03007991003689175

6. Antman E.M., Bennett J.S., Daugherty A. et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007; 115(12): 1634– 1642. DOI: 10.1161/CIRCULATIONAHA.106.181424

7. Abramova S.N., Lazareva G.A. Pharmacotherapy exacerbations of chronic inflammatory conditions of female genital sphere using to Gepon and Longidaza. Research result: pharmacology and clinical pharmacology. 2016; 2(4): 55–67. DOI: 10.18413/2500-235X2016-2-4-55-67

8. Zhurakhovskaya D.V., Loskutova E.E., Vinogradova I.A. Marketingovyi analiz farmatsevticheskogo rynka nesteroidnykh protivovospalitel’nykh preparatov na regional’nom urovne. Sovremennye Problemy Nauki i Obrazovaniya. 2014; (2). URL: http://www.science-education.ru/116-12853 (In Russ.).

9. Hawkey C.J. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology. 2000; 119(2): 521–535.

10. El-Setouhy D.A., Gamiel A.A., Badawi A.A. et al. Comparative study on the in vitro performance of blister molded and conventional lornoxicam immediate release liquitablets: accelerated stability study and anti-inflammatory and ulcerogenic effects. Pharm. Dev. Technol. 2017; 22(2): 256–265. DOI: 10.1080/10837450.2016.1221423

11. Halici Z., Polat B., Cadirci E. et al. Inhibiting renin angiotensin system in rate limiting step by aliskiren as a new approach for preventing indomethacin induced gastric ulcers. Chem. Biol. Interact. 2016; 258: 266– 275. DOI: 10.1016/j.cbi.2016.09.011

12. Mikhailov I.B. Nastol’naya kniga vracha po klinicheskoi farmakologii. Rukovodstvo dlya vrachei. Saint Petersburg: Foliant; 2001: 736 (In Russ.).

13. Bjorkman D.J. Current status of nonsteroidal anti-inflammatory drugs (NSAID) use in the United States: risk factors and frequency of complications. Am. J. Med. 1999; 107(6А): 3S–8S.

14. Bahmani M., Sarrafchi A., Shirzad H. et al. Cardiovascular toxicity of cyclooxygenase inhibitors and promising natural substitutes. Curr. Pharm. Des. 2017; 23(6): 952–960. DOI: 10.2174/138161282266616100 6144942

15. Strom B.L., Carson J.L., Schinnar R. et al. Nonsteroidal anti-inflammatory drugs and neutropenia. Arch. Int. Med. 1993: 153(18): 2119–2124.

16. Oude Munnik T.H., Annink-Smoors M., Hom H.W., Sportel E.T. Agranulocytosis and septic shock after metamizole use. Ned. Tijdschr. Geneeskd. 2016; 160: A9464.

17. Pedrazas López D., de Pablo Márquez B, García Font D., Sánchez García Е. Methamizole-induced agranulocytosis. Med Clin (Barc). 2016; 146(7): e41. DOI: 10.1016/j.medcli.2015.07.008

18. Bort R., Ponsoda X., Jover R. et al. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J. Pharmacol. Exp. Ther. 1999; 288(1): 65–72.

19. Teoh N.C., Farrell G.C. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin. Liver Dis. 2003; 7(2): 401–413.

20. Pathan E., Gaitonde S., Rajadhyaksha S. et al. A longitudinal study of serum creatinine levels in patients of rheumatoid arthritis on long term NSAID therapy. J. Ass. Phys. Ind. 2003; 51: 1045–1049.

21. Van Staa T.P., Travis S., Leufkens H.G., Logan R.F. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology. 2004; 126(7): 1733–1739.

22. Zhang X., Donnan P.T., Bell S., Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrology. 2017; 18(1): 256. DOI: 10.1186/s12882-017-0673-8

23. Beskhmelnitsyna E.A., Korokin M.V., Avtina T.V. et al. Ion channel TRPA1 is a promising therapeutic target for treatment of pain. Research result: pharmacology and clinical pharmacology. 2015; 1(1): 20–22. DOI: 10.18413/2500-235X-2015-1-4-21-24

24. Rukovodstvo po eksperimental’nomu (doklinicheskomu) izucheniyu novykh farmakologicheskikh veshchestv: uchebnoe posobie dlya sistemy poslevuzovskogo professional’nogo obrazovaniya vrachei. Federal’naya sluzhba po nadzoru v sfere zdravookhraneniya i sotsial’nogo razvitiya, Nauchnyi tsentr ekspertizy sredstv meditsinskogo primeneniya. R.U. Khabriev, ed. 2nd ed., revised and enlarged. Moscow: Meditsina; 2005: 832.